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Abstract
Background: KARS encodes lysyl- transfer ribonucleic acid (tRNA) synthetase, which catalyzes the aminoacylation of
tRNA-Lys in the cytoplasm and mitochondria. Eleven families/sporadic patients and 16 different mutations in KARS have
been reported to date. The associated clinical phenotype is heterogeneous ranging from early onset encephalopathy to
isolated peripheral neuropathy or nonsyndromic hearing impairment. Recently additional presentations including
leukoencephalopathy as predominant cerebral involvement or cardiomyopathy, isolated or associated with muscular and
cerebral involvement, have been reported. A progressive Leukoencephalopathy with brainstem and spinal cord
calcifications was previously described in a singleton patient and in two siblings, without the identification of the genetic
cause. We reported here about a new severe phenotype associated with biallelic KARS mutations and sharing some
common points with the other already reported phenotypes, but with a distinct clinical and neuroimaging picture.
Review of KARS mutant patients published to date will be also discussed.
Results: Herein, we report the clinical, biochemical and molecular findings of 2 unreported Italian patients affected by
developmental delay, acquired microcephaly, spastic tetraparesis, epilepsy, sensory-neural hypoacusia, visual impairment,
microcytic hypochromic anaemia and signs of hepatic dysfunction. MRI pattern in our patients was characterized by
progressive diffuse leukoencephalopathy and calcifications extending in cerebral, brainstem and cerebellar white matter,
with spinal cord involvement. Genetic analysis performed on these 2 patients and in one subject previously described
with similar MRI pattern revealed the presence of biallelic mutations in KARS in all 3 subjects.
Conclusions: With our report we define the molecular basis of the previously described Leukoencephalopathy with
Brainstem and Spinal cord Calcification widening the spectrum of KARS related disorders, particularly in childhood onset
disease suggestive for mitochondrial impairment. The review of previous cases does not suggest a strict and univocal
genotype/phenotype correlation for this highly heterogeneous entity.
Moreover, our cases confirm the usefulness of search for common brain and spine MR imaging pattern and of broad
genetic screening, in syndromes clinically resembling mitochondrial disorders in spite of normal biochemical assay.
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Background
KARS encodes lysyl- transfer ribonucleic acid (tRNA) syn-
thetase, which catalyzes the aminoacylation of tRNA-Lys
in the cytoplasm and mitochondria [1]. Mitochondrial and
cytoplasmic aminoacyl–tRNA synthetases (aaRSs) are
encoded by distinct nuclear genes, with the exception of
KARS and GARS (glycyl–tRNA synthetase) which are
present in both cellular compartments [2, 3].
Mutations in aaRSs genes have been linked to a grow-
ing number of neurological and systemic disorders with
heterogeneous phenotype. Eleven families/sporadic pa-
tients and 18 different mutations in KARS have been re-
ported to date. Phenotype is heterogeneous ranging
from early onset encephalopathy [4–7] to isolated per-
ipheral neuropathy [8] or nonsyndromic hearing impair-
ment [9]. Recently, late onset leukoencephalopathy [10]
and cardiomyopathy [11, 12] have been reported.
A progressive leukoencephalopathy with brainstem
and spinal cord calcifications was previously described
as a distinct entity in a singleton patient [13] and in two
siblings [14]. We report the clinical, biochemical and
molecular findings of 2 unreported patients presenting a
similar clinical and radiological picture. Genetic analysis
performed on them and in the patient previously de-
scribed [13] revealed the presence of biallelic mutations
in KARS in all three subjects. Review of KARS mutant
patients published to date will also be discussed.
Methods
All procedures followed were in accordance with the ethical
standards of the responsible committee on human experi-
mentation (institutional and national) and with the Helsinki
Declaration of 1975, as revised in 2000. Written informed
consent was obtained from all individuals or caregivers.
Genetic analysis
Genomic DNA was extracted from peripheral blood by
standard methods. Whole exome sequencing was per-
formed on DNA from patient A, while patient B and C
were analyzed using a targeted next generation sequencing
(NGS) custom panel containing genes responsible for mito-
chondrial disorders (Additional file 1). Variants filtering was
performed as previously described [15]. Variants identified
by WES were validated by Sanger sequencing and resolved
on a 3130xl Genetic Analyzer (Applied Biosystems).
Biochemical studies in skeletal muscle and fibroblasts
Mitochondrial respiratory chain (MRC) activities of
complexes I to IV were measured by spectrophoto-
metric methods in supernatants of 800 × g muscle
homogenates or in digitonin treated fibroblasts [16].
The activities were normalized to citrate synthase ac-
tivity, an index of mitochondrial content in the ana-
lyzed specimens.
Results
Clinical and radiological findings
Patient A
Patient A, first child of unrelated Italian parents, showed
a progressive leukoencephalopathy with spinal cord cal-
cifications, deafness, hypochromic microcytic anemia
and has been already described by Orcesi et al. [13].
Patient B
The patient is a 7 year old male. The family history was
unremarkable. He was born at term after an uneventful
pregnancy. He showed normal psychomotor development
until 6 months of age when, a few days after a febrile ill-
ness, he had seizures and psychomotor regression. He
started phenobarbital treatment. In the following months
he showed a slow psychomotor improvement: trunk con-
trol was recovered, he was able to walk with support at
12 months, and had been seizures free (he stopped drug at
8 months). At 18 months, after another febrile illness, he
presented subacute psychomotor regression and seizures.
Valproate treatment was initiated.
He was admitted to our institute at 3 years and 10 months
of age. Clinical evaluation showed stunted growth, micro-
cephaly (<3rd percentile), marked scoliosis, nystagmus,
poor eye contact and response to sounds, absence of spon-
taneous movements and postural control, spastic tetrapar-
esis with extrapyramidal signs, absence of language. At last
follow up, at 7 years of age, neurological conditions were
stable; seizures were not reported.
Abdominal ultrasound- performed before Valproate
treatment - disclosed hepatomegaly, echocardiogram was
normal. Fundus oculi performed at 6 months disclosed
bilateral optic atrophy; since 3 years of age, visual evoked
potential showed absence of any responses; brainstem
auditory evoked potential suggested profound sensori-
neural hypoacousia, pure tone audiometry was not
performed. Serial EEG revealed poor organization of
cerebral activity and multifocal abnormalities. MRI was
normal at 6 months. A second MRI (1 year and 9 months)
revealed diffuse signal abnormalities in deep cerebellar
white matter (WM), middle cerebellar peduncles, brain-
stem and bi-hemispheric WM (Fig. 1a-e). A third MRI
(3 years and 10 months), (Fig. 1h-j) disclosed extension
of the diffuse signal abnormalities in bi-hemispheric
WM, involving the U fibers (Fig. 1i, j). There was also full
involvement of the posterior arm of the internal capsules,
external capsules, thalami, cerebellar WM, cerebellar pe-
duncles and brainstem (Fig. 1f-i).T2 shine-through effect
on DWI was evident in the areas of the T2 signal abnor-
malities. Bilateral Calcarine cortex had a malacic appear-
ance, with a gliotic hyperintensity on T2 and focal
atrophy. Diffuse cerebral atrophy was also documented
(Fig. 1f-i). Spectroscopy showed reduction of NAA and
lactate in the centrum semiovale.
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Cranial CT showed calcifications particularly in the
periventricular WM, but also evident in the cerebellar
WM, pons, thalami, internal capsules and calcarine cor-
tex (Fig. 2a-c). The last brain MRI and CT examinations
(7 years) showed worsening of cerebral and cerebellar at-
rophy and increased cerebral calcifications.
Spinal MRI disclosed on T2WIslight hyperintensity in
the lateral columns of both cervical and dorsal spinal
cord (Fig. 2j) and spinal CT disclosed calcifications at
C6-T1 level.
Blood routine disclosed microcytic hypochromic anemia
and mild elevated transaminase levels since first evalu-
ation before valproate treatment. Galactocerebrosidase,
arylsulfatases were normal. Plasma lactate and pyruvate
levels were elevated: 2872–3042 μmol/l (n.v. 580–2100)
and 171 μmol/l (n.v. 5–145) respectively, normal in CSF.
Amino acids, creatine and guanidinoacetate were normal.
Genetic screening using NGS panel for Aicardi-Goutieres
syndrome was negative. A mitochondrial diseases was sus-
pected, muscle biopsy was not possible because of marked
hypotrophy. MRC complexes and pyruvate dehydrogenase
(PDH) complex activities resulted normal in fibroblasts;
analysis of POLG was negative.
Patient C
This girl was born at term after normal pregnancy and
delivery from healthy unrelated parents. At 2 months of
age parents started to suspect hearing impairment and
at 6 months bilateral cochleopathy was diagnosed on the
basis of a type A tympanogram and brainstem auditory
evoked potential.
At 12 months she came to our attention. Neurological
evaluation showed spastic tetraplegia and microcephaly;
she was able to fixate and track a visual target, but was
not able to reach an object; spontaneous movements
were poor and non-finalized, postural controls absent.
At last follow up, at 18 months of age, neurological con-
ditions were stable.
Cerebral MRI (at 6, 12 and 18 months) showed progres-
sive bilateral diffuse supra e infra-tentorial WM abnormal-
ities with involvement of centrum semiovale, corona
radiata, initially sparing U fibers; there was also involvement
of the posterior arm of the internal capsules, external cap-
sules, thalami, cerebellar and deep WM and brainstem,
while putamina were relatively spared. In particular, in the
brainstem we noticed bilateral symmetric hyperintensities
in the bulbar pyramids and lateral regions, involvement of
the superior cerebellar peduncles and in the arciform fibers
of their decussation at the level of the mesencephalon. Both
V cranial nerves appeared slightly hyperintense on T2WI.
Progressive cerebral calcifications were also evident on CT
(Fig. 2d-f), initially involving internal capsules, deep and
periventricular WM (at 6 months) and since 12 months
dentate nuclei.
Spinal MRI performed at 12 months documented bi-
lateral hyperintensities on T2WI in the cervical and
Fig. 1 MRI in patient B. TOP, Axial T2WI. performed at 1 year and 9 months revealed diffuse hyperintensity in deep cerebellar white matter,
middle cerebellar peduncles, brainstem and bi-hemispheric white matter (a, b, c, d). The signal is inhomogeneous for the presence of multiple
focal marked hypointensities due to calcifications (e, arrows). BOTTOM, Axial T2WI. performed at 3 years and 10 months showed a dramatic extension of
the diffuse signal abnormalities in both hemispheres with full involvement of the posterior arm of the internal capsules, external capsules, U fibers and
thalami, with relative sparing of the putamina (h-j). The signal abnormalities extension was also evident in cerebellar white matter, cerebellar peduncles
and brainstem (f, g). Bilateral symmetric hyperintensities in the bulbar pyramids and bulbar lateral regions (arrowheads in f), in the superior cerebellar
peduncles and in the arciform fibers of their decussation (arrowheads in H) were more evident. The transverse fibers of the pons were prominent and
hyperintense (insert in g). Both V cranial nerves appeared swollen and hyperintense (stars in g), as well as the optic chiasm. Calcarine cortex showed a
gliotic hyperintensity (black arrows in c). A huge diffuse cerebral atrophy with ventricles and sulci dilatation associated with pronounced cortical thickness
was also observed
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dorsal lateral columns (Fig. 2j) and CT showed calcifica-
tions at 12 and 18 months.
Visual evoked potentials was slightly delayed at
12 months and severely abnormal at 18, electroretinogram
was normal, fundus oculi showed diffuse mild depigmen-
tation; peripheral nerves conductions were normal; EEG
showed poor organization of background activity with
fronto-centro-temporal spikes at 12 months, increased at
18 months.
Biochemical exams revealed microcytic hypochromic
anaemia with normal iron concentration, high level of
plasma lactate (3312 μmol/l) and pyruvate (199 μmol/l)
with normal CSF concentration. MRC complexes activ-
ities resulted normal in fibroblasts.
Abdominal ultrasound revealed inhomogeneous echo-
genicity, with nodular aspects, liver function tests showed
slight elevation of serum transaminases, with normal syn-
thetic function and no signs of cholestasis. Liver biopsy
showed mild portal sclerosis with mild distortion of ven-
ous portal vessels, without any significant inflammatory
infiltrate; lobular parenchyma demonstrated focal enlarged
trabeculae with compression of the peripheral hepato-
cytes, and preserved reticular network without fibrosis.
These findings were suggestive of a vascular disturbance
with nodular regenerative hyperplasia (Fig. 3).
Genetic studies
Whole exome sequencing was performed on patient A;
following a filtering strategy that enriched for rare
(MAF of < 1%) nonsynonymous/splice variants that
segregated in a recessive manner, a short list of candi-
date genes was obtained but without any known gene
associated with WM disease (Additional file 2). Inde-
pendently, NGS-based screening of genes associated
with mitochondrial disorders performed on patient B
disclosed two heterozygous variants in KARS (NM_
001130089.1): c.1124A > G/p.Tyr375Cys and c.381C >
G/p.Phe127Leu. These variants and their segregation in
the family were confirmed by Sanger sequencing.
Given the striking similarities of clinical and neuroim-
aging features between patient B and patient A, WES
data from the latter were reconsidered and a likely
causative role was assigned to the homozygous variant c.
1514G > A/p.Arg505His in KARS. Similarly, because of
her clinical presentation an NGS-based screening of
KARS was performed on patient C, leading to the identi-
fication of two heterozygous variants: c.815 T > G/p.
Phe272Cys and c.1043G > A/p.Arg348His. All the identi-
fied KARS variants had an extremely low frequency in
public databases (< 0.01%), are predicted to be deleteri-
ous and hit phylogenetically conserved amino acid resi-
dues, supporting their causative role (Additional file 3).
Notably, the c.1514G > A/p.Arg505His found in patient
A has been recently reported in compound heterozygos-
ity with another missense change in two siblings with
early-onset hearing loss and leukoencephalopathy and
its pathogenicity has been experimentally proven [10].
Discussion
Mutations in different aaRSs have been associated with
an increasing number of phenotypes [2, 3]. Encephalop-
athy is the most common phenotype, but other extra
neurological symptoms have been reported: sideroblas-
tic anemia (YARS2 [17, 18]), cardiomyopathy and
myopathy (YARS2 [19], GARS [20], KARS [11, 12],
tubulopathy (SARS2 [21]), ovarian failure (AARS2 [22],
HARS2 [23], LARS2 [24]), hepatopathy (FARS2 [25],
EARS2 [26]) and hearing loss (HARS2 [23], LARS2
[25], KARS [9]).
Fig. 2 Axial CT images of Patient B (a, b, c) and patient C (d, e, f) during different stages of the diseases, showing “rocks” calcifications in the
cerebellar white matter (a, d), pons (a), periventricular white matter, thalami (b, e), and in the internal capsules, where they have a peculiar
«boomerang appearance» (e, arrows) and centrum semiovale (c, f). Spine sagittal (g) and axial (h) CT of patient A showing extensive «track-like»
calcifications along the whole spinal cord, well seen also on axial T2-fast field echo (FFE) MR images at the dorsal level and located in the region
of the anterior horns (i). Axial T2-FFE MR image of patient C depicts the bilateral hyperintensities on T2WI in the dorsal lateral columns (j arrows)
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Up to now, 11 families/sporadic patients and 18 muta-
tions in KARS have been reported (Tables 1 and 2).
KARS impairment was first linked to peripheral neur-
opathy [8] in one patient (Pt 1) presenting with Charcot-
Marie-Tooth neuropathy, developmental delay, self-
abusive behavior, dysmorphic features, and vestibular
Schwannoma. Compound heterozygous p.Leu133His
and p.Tyr173SerfsX7 variants were identified. Functional
analyses revealed that these two mutations severely
affect enzyme activity.
Autosomal recessive nonsyndromic hearing loss was
the second phenotype reported [9]. In affected individ-
uals homozygosity for missense mutations (p.Asp377Asn
or p.Tyr173His) in KARS was identified. (Pts 2–14/Fam.
2–4). Both variants were predicted to be damaging by
multiple bioinformatics tools. The first case of KARS
mutations associated with suspected mitochondrial dis-
ease was reported in 2013 [4]. The authors analyzed by
exome sequencing a series of 102 patients with clinical
and biochemical findings suggestive for mitochondrial
disorders and identified compound heterozygous KARS
mutations (p.Thr587Met; p.Pro228Leu) in a patient af-
fected by psychomotor delay, hearing loss, ophthalmo-
plegia, dystonia and elevated CSF lactate level (Pt 15/
Fam. 5). MRC activity on tissue was not investigated. No
experimental proof was reported but, given the predicted
severity of the mutations at highly conserved residues,
the authors concluded that the observed mutations were
likely the genetic cause of patient’s phenotype.
A more severe phenotype was reported in two 2 siblings
(Pts 16–17/Fam. 6) with early onset visual impairment,
progressive microcephaly, developmental delay, seizures
and very subtle deep white matter loss on MRI [5]. The
patients harbored compound heterozygous mutations (p.
Arg466Trp; p.Glu553Lys) within a highly conserved re-
gion of the catalytic domain. A similar clinical presenta-
tion was reported in a patient who harbored a p.Ala57Pro
missense change and a 7601-base pair deletion, encom-
passing the first three exons of the mitochondrial isoform
of KARS (Pt 18/Fam. 7) [6]. Cardiac involvement associ-
ated with a deficiency of MRC complexes I and IV has
been reported in two patients (Pts 19–20/Fam. 8–9), who
carried novel biallelic KARS mutations [11, 12]. The first
one presented a childhood-onset hypertrophic cardiomy-
opathy associated with seizures, developmental delay, in a
patient harboring compound heterozygous p.Val476Asp
and p.Ile346Thr mutations [11] while hypertrophic cardio-
myopathy was the clinical hallmark in the second, a
14 years old patient with mild myopathic signs and cogni-
tive disability (in spite of normal brain MRI) associated
with p.Leu378His and p.Pro418Arg [12]. In both patients
lactic acidosis was detected. In the first case, the mito-
chondrial enzyme defects were rescued by cDNA comple-
mentation with mitochondrial KARS, but not cytosolic
form [11]. More recently, two mutations (p.Arg505His; p.
Pro533Ser) have been reported in two siblings affected by
early onset hearing loss, progressive cognitive impairment
and psychiatric symptoms with onset in adulthood associ-
ated with leukoencephalopathy: brain MRI showed
symmetrical confluent abnormalities in the frontal, peri-
ventricular white matter and in the corpus callosum [10].
Functional studies showed that both mutations decreased
Fig. 3 Histological liver changes in patient C: mild sclerotic portal space with irregular venous vessels (a, hematoxylin and eosin stain, 200×); vaguely
nodular lobular area with compressed peripheral trabeculae (arrows) can be highlighted by Masson’s trichrome (b, 100×) and Reticulin (c, 100×)
stainings, and CD34 immunohistochemistry (d, 100×)
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Table 1 Clinical, instrumental, biochemical and molecular findings in published patients with KARS mutations
Patient Family Age onset Symptoms at onset Clinical finding Brain MRI Visceral
involvement/
systemic
symptoms
Age at last
follow up
Reference
Pt 1 Fam. 1 Adulthood Intermediate CMT, developmental delay, self-
abusive behavior, dysmorphic features, and
vestibular Schwannoma
n.a. n.a. n.a. McLaughlin
HM et al.
2010 [8]
Pts 2–8 Fam. 2 Childhood Nonsyndromic hearing impairment n.a. n.a. n.a. Santos-
Cortez RL et
al. 2013 [9]
Pts 9–14 Fam. 3–4 Childhood Nonsyndromic hearing impairment n.a. n.a. n.a. Santos-
Cortez RL et
al. 2013 [9]
Pt 15 Fam. 5 16 months n.a. Psychomotor delay,
hearing loss,
strabismus,
ophthalmoplegia,
dystonia
Normal (6 months) n.a. Died at
3 years
Lieber et al.
2013 [4]
Pt 16 Fam. 6 6 weeks Visual impairment Microcephaly,
psychomotor delay,
seizures
Symmetrical thinning of
cerebral WM and the corpus
callosum (9 months);
progression of myelination,
symmetrical deep WM
abnormalities (20 months)
n.a. 10 years McMillan et
al. 2015 [5]
Pt 17 5 weeks Thin cc (4 months); loss of
subcortical white matter
volume, deep sulcation, and
hypogenesis cc (5.3 years)
n.a. 5 years McMillan et
al. 2015 [5]
Pt 18 Fam. 7 72 days Nystagmus, failure
to thrive, inability to
fixate, microcephaly,
hypertonicity, and
extreme irritability
Microcephaly and
failure to thrive,
psychomotor delay,
seizures (West
syndrome)
Normal (age not reported) n.a. 18 months Joshi et al.
2016 [6]
Pt 19 Fam. 8 9 months n.a. Developmental delay,
seizures, nystagmus
n.a. Hypertrophic
cardiomyopathy
n.a. Kohda et al.
2016 [11]
Pt 20 Fam. 9 18 months Mild psychomotor
delay
Mild myopathy,mild
intellectual disability
Normal (13 years) Hypertrophic
cardiomyopathy
14 years Verrigni et
al. 2016 [12]
Pts 21–
22
Fam. 10 First years Hearing loss Hearing loss, cognitive
and psychiatric
symptoms
Symmetrical confluent
abnormalities in the frontal,
periventricular WM and in the
cc
no 26–
21 years
Zhou et al.
2017 [10]
Pt 23 Fam. 11 First
months
Developmental
delay, microcephaly
Global developmental
delay, microcephaly,
hypotonia, seizures and
sensorineural hearing
loss
n.a. (CT: calcification) n.a. 18 years Murray et
al. 2017 [7]
Pt 24 First
months
Hearing loss n.a. n.a. 15 years
Pt 25 Fam. 12 3 months Hypoacousia Severe psychomotor
delay, microcephaly,
visual impairment,
spastic tetraparesis
Progressive
Leukoencephalopathy with
Brainstem and Spinal cord
Calcifications (see text for
detail)
Microcytic
hypochromic
anemia
19 months This report
(Pt A);
Orcesi et al.
2011 [13]
Pt 26 Fam. 13 6 months Seizures and
psychomotor
regression
Severe psychomotor
delay, microcephaly,
visual impairment,
spastic tetraparesis with
extrapyramidal
signs,scoliosis
Progressive
Leukoencephalopathy with
Brainstem and Spinal cord
Calcifications (see text for
detail)
Hepatomegaly/
microcytic
hypochromic
anemia
7 years This report
(Pt B)
Pt 27 Fam. 14 6 months hypoacousia Psychomotor delay,
microcephaly, visual
impairment, spastic
tetraplegia
Progressive
Leukoencephalopathy with
Brainstem and Spinal cord
Calcifications (see text for
detail)
Hepatopathy/
microcytic
hypochromic
anaemia
18 months This report
(Pt C)
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tRNA aminoacylation while p.Arg505His changed the sec-
ondary structure of KARS, leading to protein aggregation.
Finally, KARS mutations (p.Ala526Val; p.Phe489Cys) were
reported in two sisters affected by developmental delay,
microcephaly, seizures, and sensorineural hearing loss;
calcifications of left occipitoparietal junction were re-
ported in one case (Pt 23). MRC enzymes activity in
muscle biopsy was normal, lactate level was not available
(Pt 24) [7].
In the present manuscript we reported about a new se-
vere phenotype associated with biallelic KARS mutations.
Our patients presented an early onset and progressive
encephalopathy characterized by acquired microcephaly,
developmental delay, spastic tetraparesis, epilepsy, sensori-
neural hypoacusia, visual impairment, microcytic hypo-
chromic anaemia and failure to thrive. In addition patients
B and C presented liver involvement. To our knowledge,
this is the first report of hepatic involvement in this disease
but the exact meaning of the reported anomalies has still
to be understood. Nevertheless, in patient A no evi-
dence of liver dysfunction was reported and liver
ultrasound was normal.
In patient B, the severity of the phenotype, the clinical
onset related to febrile illness and the presence of lactic
acidosis suggested a mitochondrial disease that was
directly investigated in spite of normal MRC and PDH
activities in fibroblasts.
In patient C, clinical picture and lactic acidosis claimed
the idea of a mitochondrial disorder as already suggested
also in patient A, supported by mild lactate elevation at
spectroscopy study. In KARS-mutant cases reported to
date, mitochondrial disease was suspected and confirmed
by biochemical diagnosis only in patients with cardiomyop-
athy (Pt 19 and Pt 20); elevated lactate level in CSF was de-
tected in Pt 15 but biochemical studies on tissue were not
performed. In other cases, metabolic analyses for mito-
chondrial disease were unremarkable or not performed. In
5 of 26 KARS patients reported to date, including our cases,
both lactate level and biochemical studies (in different tis-
sues) were performed and only in patients with cardiac in-
volvement elevated lactate level corresponded to reduced
MRC activity. Nevertheless the lack and heterogeneity of la-
boratory data does not permitted this phenotypic variability
explanation. The MRI findings were similar in all three
patients and characterized by progressive diffuse leukoence-
phalopathy and calcifications extending in cerebral, brain-
stem and cerebellar WM, with spinal cord involvement.
Specifically, at the early stages of the disease the signal ab-
normalities were observed in the deep cerebellar WM and
in the centrum semiovale. Progressively, an extensive
Table 2 biochemical and molecular findings in published patients with KARS mutations
Patient Family Nucleotide mutations Protein change(s) Lactate MRC activity Reference
Pt 1 Fam. 1 c.398 T > A; c.514_515insTT p.Leu133His;
p.Tyr173Serfs*9
n.a. n.a. McLaughlin HM et al.
2010 [8]
Pts 2–8 Fam. 2 c.1129G > A; c.1129G > A p.Asp377Asn n.a. n.a. Santos-Cortez RL et al.
2013 [9]
Pts 9–14 Fam.
3–4
c.517 T > C; c.517 T > C p.Tyr173His n.a. n.a. Santos-Cortez RL et al.
2013 [9]
Pt 15 Fam. 5 c.1760C > T; c.683C > T p.Thr587Met;
p.Pro228Leu
Elevated (CSF) n.a. Lieber et al. 2013 [4]
Pt 16 Fam. 6 c.1396C > T; c.1657G > A p.Arg466Trp;
p.Glu553Lys
Normal (plasma) n.a. McMillan et al. 2015 [5]
Pt 17 n.a. n.a. McMillan et al. 2015 [5]
Pt 18 Fam. 7 c.169G > C; deletion at
chr16:75672800–75,680,400
p.Ala57Pro; loss of
starting codon
n.a. n.a. Joshi et al. 2016 [6]
Pt 19 Fam. 8 c.1037 T > C; c.1427 T > A p.Ile346Thr;
p.Val476Asp
Elevated cI-IV defects
(fibroblast)
Kohda et al. 2016 [11]
Pt 20 Fam. 9 c.1133 T > A; c.1253C > G p.Leu378His;
p.Pro418Arg
Elevated cI-IV defects
(muscle)
Verrigni et al. 2016 [12]
Pts 21–22 Fam. 10 c.1514G > A; c.1597C > T p.Arg505His;
p.Pro533Ser
n.a. n.a. Zhou et al. 2017 [10]
Pt 23 Fam. 11 c.1577C > T; c.1466 T > G p.Ala526Val;
p.Phe489Cys
n.a. n.a. Murray et al. 2017 [7]
Pt 24 n.a. Normal (muscle)
Pt 25 Fam. 12 c.1514G > A; c.1514G > A p.Arg505His Normal (plasma and
CSF)
cI, I + III,II + III
defects (muscle)
This report (Pt A); Orcesi
et al. 2011 [13]
Pt 26 Fam. 13 c.1124A > G; c.381C > G p.Tyr375Cys;
p.Phe127Leu
Elevated (plasma),
normal (CSF)
Normal (fibroblasts) This report (Pt B)
Pt 27 Fam. 14 c.815 T > G; c.1043G > A p.Phe272Cys;
p.Arg348His
Elevated (plasma),
normal (CSF)
Normal (fibroblasts) This report (Pt C)
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diffuse WM involvement, including U fibers, posterior arm
of the internal capsules, external capsules, thalami, cerebel-
lar peduncles and brainstem, with selective bilateral sym-
metric involvement of the bulbar pyramids and lateral
bulbar regions resembling the pattern of mitochondrial dis-
eases were observed. The supratentorial WM involvement
was characterized by uniform slight hyperintensity on
T2WI, interrupted by marked foci of hypointensities due to
calcifications. This appearance seems to be due to a demye-
linating process an assumption supported also by the evi-
dence of demyelination of the proximal intracisternal
portion of the V cranial nerves (Fig. 1g).
Cerebral calcifications have a distinct pattern with ini-
tial involvement of deep cerebellar and cerebral periven-
tricular WM and progressive extension to the thalami
and internal capsules, in which a peculiar “boomerang
appearance” was present. Calcifications were evident
even in the initial phases of the disease and might not be
a dystrophic epiphenomenon and so a secondary and
aspecific event, but an intrinsic feature of the disorder.
In the spine they were present in all 3 patients, even if
with different severity, and were characterized by a pe-
culiar bilateral and symmetrical distribution in the anter-
ior horns, both extensively (Patient A) or spot-like
(Patients B and C). On MRI, bilateral abnormal signal
intensity in the lateral columns was also associated.
Patient B dysplayed a more severe cerebral atrophy
and grey matter involvement (basal ganglia and cortex)
but he underwent the first MRI later in life compared to
the other two. As disease progressed, the radiological
picture evolved toward a progressive cerebral atrophy in
2 patients (A and B).
WM involvement has been previously reported in few
KARS-mutant patients but with a less severe pattern and
restricted to supratentorial regions (Pt 16, Pt 17, Pt 21,
Pt 22). It is interesting to note that the presence of cere-
bral WM and spinal cord signal abnormalities is a pretty
rare association of neuroradiological features and it is
typically observed in other aaRSs deficiencies, notably in
DARS and DARS2 related leukodystrophies [27, 28]. It is
also a quite common finding in Iron-sulfur cluster re-
lated leukoencephalopathies, particularly those caused
by GLRX5 [29], ISCA2 [30], or IBA57 [31] mutations.
The association of cerebral WM abnormalities with
spinal cord involvement should prompt to consider
aaRSs-related diseases and particularly KARS mutations
when calcifications are observed.
The extremely heterogeneous clinical presentation associ-
ated with KARS mutations is peculiar in the field of aaRS-
related diseases which are usually characterized by strict
genotype-phenotype associations, although a definite ex-
planation of the molecular mechanisms underpinning this
observation is still missing. Few examples of different phe-
notypes caused by mutations in the same aaRS gene have
been reported (e.g. AARS2 associated with either cardiomy-
opathy or leukoencephalopathy and ovarian failure
[22, 32]). Differences in mode of inheritance and type of
mutation cannot easily explain the variable clinical presen-
tations since all the reported cases showed an autosomal re-
cessive transmission of missense mutations. Only the
patient described by Joshi et al. (Pt 18/Fam. 7) carried a
large deletion, acting as a null allele, together with a mis-
sense mutation which disrupts the mitochondrial targeting
signal, thus potentially affecting solely the mitochondrial
isoform of KARS. All the other patients, irrespective of any
evidence of mitochondrial dysfunction, harbored KARS var-
iants which are predicted to strike both mitochondrial and
cytosolic KARS isoforms. An effect of the affected func-
tional domains was initially suggested, since the first muta-
tions responsible for the neuropathic phenotype hit the
anticodon domain whereas hearing loss associated muta-
tions could be in the catalytic domain. However this hy-
pothesis was not confirmed in the following reports and in
the present review of all the KARS mutant patients. For in-
stance, the mutations found in our patients, with an over-
lapping phenotype, are scattered throughout the gene
(from amino acid 127 to 505) and affect either the
anticodon-binding or the catalytic domain. The few func-
tional studies which have been performed indicated that
various functions/properties of KARS (e.g. tRNA aminoacy-
lation, secondary structure) may be affected by different
mutations. Nevertheless, no genotype/phenotype correl-
ation was evident, even considering the residual enzymatic
activity of the different mutant forms. Nevertheless a muta-
tion specific effect cannot be excluded, since all the identi-
fied KARS mutations were reported in single cases/families;
for instance, the cardiac phenotype in AARS2 mutant
patients seems to be strictly linked to the presence of
a specific amino acid change. The only KARS muta-
tion presents in two unrelated families was the p.
Arg505His, identified in homozygosity in patient A
and in compound heterozygosity with p.Pro533Ser in
Pts 21–22; all these three individuals were character-
ized by leukodystrophy and hearing problems but the
MRI features were not identical and other clinical
symptoms were different (e.g. visual impairment and
spastic tetraparesis were observed in patient A but not
in the two siblings). Obviously, the partially different
genotype may account for the phenotype diversities.
Conclusion
With our report we define the molecular basis of the
previously described Leukoencephalopathy with Brain-
stem and Spinal cord Calcification, that we propose
to call LBSC similarly to DARS and DARS2 related
leukodystrophies, widening the spectrum of KARS re-
lated disorders, particularly in childhood onset disease
suggestive for mitochondrial impairment. The review
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of previous cases does not suggest a strict and uni-
vocal genotype/phenotype correlation for this highly
heterogeneous entity.
Moreover, our cases confirm the usefulness of search
for common brain and spine MR imaging pattern and of
broad genetic screening, in syndromes clinically resem-
bling mitochondrial disorders in spite of normal bio-
chemical assay.
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